ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Treatment regimens for native valve endocarditis due to Staphylococcus

Treatment regimens for native valve endocarditis due to Staphylococcus
American Heart Association (AHA) European Society of Cardiology* (ESC) British Society for Antimicrobial Chemotherapy (BSAC)
Adult Pediatric
Methicillin-susceptible strains Methicillin-susceptible strains Methicillin-susceptible strainsΔ Methicillin sensitive

Nafcillin or oxacillin 12 g per 24 hours IV in four or six divided doses for 6 weeks

or

Cefazolin 6 g per 24 hours IV in three divided doses for 6 weeks

Nafcillin or oxacillin 200 mg/kg per 24 hours IV (maximum dose: 12 g per 24 hours) in four or six divided doses for 4 to 6 weeks

or

Cefazolin 100 mg/kg per 24 hours IV (maximum dose: 6 g per 24 hours) in three divided doses for 4 to 6 weeks
Oxacillin or cloxacillin or flucloxacillin 12 g per 24 hours IV in four or six divided doses for 4 to 6 weeks

or

Cefazolin 6 g per 24 hours IV in three divided doses for 6 weeks

or

Cefotaxime 6 g per 24 hours in three divided doses

Flucloxacillin 2 g IV every 4 to 6 hours for 4 weeks
Methicillin-resistant strains Methicillin-resistant strains§ Methicillin-resistant strainsΔ Methicillin resistant

Vancomycin¥ for 6 weeks

or

Daptomycin ≥8 mg/kg per 24 hours IV once daily for 6 weeks

Vancomycin¥ 40 mg/kg per 24 hours IV (maximum dose: 2 g per 24 hours unless levels are inappropriately low) in two or three divided doses for 6 weeks

Vancomycin¥ 30 to 60 mg/kg per 24 hours IV in two or three divided doses for 4 to 6 weeks

or 

Daptomycin 10 mg/kg per 24 hours IV once daily for 4 to 6 weeks

Vancomycin¥ 1 g IV every 12 hours for 4 weeks

plus

Rifampicin 300 to 600 mg orally every 12 hours for 4 weeks

OR

Daptomycin 6 mg/kg IV every 24 hours for 4 weeks

plus

Rifampicin 300 to 600 mg orally every 24 hours for 4 weeks

or

Gentamicin 1 mg/kg IV every 12 hours for 4 weeks

The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.
IV: intravenously; IM: intramuscularly; AUC: area under the concentration-time curve.
* Pediatric doses (should not exceed adult doses): oxacillin, cloxacillin, or flucloxacillin: 200 to 300 mg/kg per 24 hours IV in four or six divided doses; trimethoprim-sulfamethoxazole (cotrimoxazole) 12 mg/kg trimethoprim component per 24 hours IV in two divided doses; clindamycin 40 mg/kg per 24 hours IV in three divided doses; vancomycin 40 mg/kg per 24 hours IV in two or three divided doses; daptomycin 10 mg/kg per 24 hours IV once daily.
¶ Regimens for complicated right-sided and all left-sided infective endocarditis.
Δ Another alternative regimen for S. aureus consists of trimethoprim-sulfamethoxazole (cotrimoxazole) 960 mg trimethoprim/4800 mg sulfamethoxazole per 24 hours IV in four or six divided doses for 1 week followed by 5 weeks of oral trimethoprim-sulfamethoxazole plus clindamycin 1800 mg per 24 hours IV in three divided doses for 1 week.
◊ For use in patients with nonsevere penicillin allergy. Avoid cefazolin in complicating brain abscess; nafcillin is preferred.
§ Consultation with a pediatric infectious disease specialist is recommended in cases of infection due to methicillin-resistant strains.
¥ Vancomycin dosing in the 2015 AHA guidelines[1] consists of 30 mg/kg per 24 hours IV in two divided doses for 6 weeks, with target trough concentrations of 15 to 20 mcg/mL. Per guidelines issued in 2020[5], vancomycin dosing consists of a loading dose: 20 to 35 mg/kg based on actual body weight, rounded to the nearest 250 mg increment and not exceeding 3000 mg; within this range, we use a higher dose for critically ill patients. The initial maintenance vancomycin dose and interval are determined by nomogram and typically consists of 15 to 20 mg/kg every 8 to 12 hours for most patients with normal kidney function. The subsequent vancomycin dose and interval adjustments are based on AUC-guided (preferred) or trough-guided serum concentration monitoring. Refer to the UpToDate topic on vancomycin dosing for sample nomogram and discussion of AUC-guided and trough-guided vancomycin dosing.
‡ Daptomycin selection and dosing should be assisted by infectious diseases consultation.
† Daptomycin is superior to vancomycin for S. aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L. Some experts recommend adding cloxacillin 12 g per 24 hours IV in six divided doses or fosfomycin 8 g per 24 hours IV in four divided doses to daptomycin in order to increase activity and avoid development of daptomycin resistance.
Data from:

  1. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.
  2. Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.
  3. Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.
  4. Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.
  5. Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus Aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.
Graphic 81429 Version 16.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟